GlassScriptPhysician profile
Steven John Sims
NPI 1316302151
$4,186.84
in general payments reported to CMS, 2019-2025
22 companies · $1,975 in 2025
The $1,975 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $268 · 2022: $41.21 · 2023: $462 · 2024: $1,441 · 2025: $1,975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,695 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,694.98 |
| Education | $183.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $909.29 | 2021-2025 | Trelegy Ellipta, Nucala |
| Actelion Pharmaceuticals US, INC. | $549.98 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| Grifols USA, LLC | $349.30 | 2023-2025 | Prolastin-C Liquid |
| Viatris Specialty LLC | $328.19 | 2025 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $322.76 | 2024-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $318.30 | 2023-2025 | Ofev, Jascayd, Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $243.33 | 2023-2025 | Breztri, Airsupra |
| Insmed, INC. | $242.24 | 2024-2025 | Arikayce, Brinsupri |
| Takeda Pharmaceuticals U.S.A., INC. | $184.82 | 2024-2025 | Glassia |
| Baxter Healthcare | $139.24 | 2023-2025 | Hillrom - Life 2000 Ventilation System, Hillrom - Monarch Airway Clearance System, Hillrom - Vest System Model 105 Home Care |
| Philips North America LLC | $130.30 | 2023-2025 | (O58) Sleep Respiratory Care Und, Encore |
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 | |
| Electromed, INC. | $66.69 | 2025 | Smartvest |
| Verona Pharma, INC. | $61.88 | 2025 | Ohtuvayre |
| Abbott Laboratories | $61.73 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $39.69 | 2023 | |
| Ani Pharmaceuticals, INC. | $33.45 | 2025 | Purified Cortrophin Gel |
| Paratek Pharmaceuticals, INC. | $29.66 | 2025 | Nuzyra |
| Merck Sharp & Dohme LLC | $27.37 | 2025 | Winrevair |
| Vifor Pharma, INC. | $26.21 | 2024 | Zemaira |
| 3b Medical, INC. | $22.57 | 2025 | Luna |
| Genzyme Corporation | $20.85 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Sims listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.